



Intracranial Pressure and Cerebral Perfusion Pressure in Large Spontaneous Intracranial Hemorrhage and Impact of Minimally Invasive Surgery

Mais N. Al-Kawaz¹, Yunke Li², Richard E. Thompson³, Radhika Avadhani², Adam de Havenon⁴, Joshua Gruber², Issam Awad⁵, Daniel F. Hanley² and Wendy Ziai^{1,2*}

¹ Neurosciences Critical Care Division, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, ² Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University, Baltimore, MD, United States, ³ Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States, ⁴ Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, United States, ⁵ Department of Neurosurgery, University of Chicago Pritzker School of Medicine, Chicago, IL, United States

OPEN ACCESS

Edited by:

Rajiv Advani, Oslo University Hospital, Norway

Reviewed by:

Benjamin Aaron Emanuel, University of Southern California, United States Syed Omar Shah, Thomas Jefferson University, United States

> *Correspondence: Wendy Ziai weziai@jhmi.edu

Specialty section:

This article was submitted to Neurocritical and Neurohospitalist Care, a section of the journal Frontiers in Neurology

> Received: 23 June 2021 Accepted: 30 July 2021 Published: 26 August 2021

Citation:

Al-Kawaz MN, Li Y, Thompson RE, Avadhani R, de Havenon A, Gruber J, Awad I, Hanley DF and Ziai W (2021) Intracranial Pressure and Cerebral Perfusion Pressure in Large Spontaneous Intracranial Hemorrhage and Impact of Minimally Invasive Surgery. Front. Neurol. 12:729831. doi: 10.3389/fneur.2021.729831 **Introduction:** We investigated the effect of hematoma volume reduction with minimally invasive surgery (MIS) on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in patients with large spontaneous intracerebral hemorrhage (ICH).

Methods: *Post-hoc* analysis of the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE III) study, a clinical trial with blinded outcome assessments. The primary outcome was the proportion of ICP readings ≥20 and 30 mmHg, and CPP readings <70 and 60 mm Hg. Secondary outcomes included major disability (modified Rankin scale >3) and mortality at 30 and 365 days. We assessed the relationship between proportion of high ICP and low CPP events and MIS using binomial generalized linear models, and outcomes using multiple logistic regression.

Results: Of 499 patients enrolled in MISTIE III, 72 patients had guideline based ICP monitors placed, 34 in the MIS group and 38 in control (no surgery) group. Threshold ICP and CPP events $\geq 20/<70$ mmHg occurred in 31 (43.1%) and 52 (72.2%) patients respectively. On adjusted analyses, proportion of ICP readings ≥ 20 and 30 mmHg were significantly lower in the MIS group vs. control group [Odds Ratio (OR) 0.27, 95% Confidence Interval [CI] 0.11–0.63 (p = 0.002); OR = 0.18, 0.04–0.75, p = 0.02], respectively. Proportion of CPP readings <70 and 60 mm Hg were also significantly lower in MIS patients [OR 0.31, 95% CI 0.15–0.63 (p = 0.001); OR 0.30, 95% CI 0.11–0.83 (p = 0.02)], respectively. Higher proportions of CPP readings <70 and 60 mm were significantly associated with short term mortality (p = 0.04), and (p = 0.006), respectively. Long term mortality was significantly associated with higher proportion of time with ICP \geq 20 (p = 0.04), ICP \geq 30 (p = 0.04), and CPP < 70 mmHg (p = 0.01).

1

Conclusion: Our results are consistent with the hypothesis that surgical reduction of ICH volume decreases proportion of high ICP and low CPP events and that these variables are associated with short- and long-term mortality.

Keywords: intracerebral hemorrage, intracranial pressure, cerebral perfusion pressure, minimally invasive surgeries, intracranial pressure monitoring

INTRODUCTION

Intracerebral hemorrhage (ICH) represents 10-15% of all strokes worldwide but imposes significant morbidity and mortality. Approximately, 10-30 patients per 100,000 are affected annually with a case fatality as high as 40% at 1 month and 54% at 1 year (1). Deleterious outcomes in ICH are a result of primary and secondary pathologic insults. Primary ICH insult is inflicted mostly by mechanical mass effect secondary to clot formation (2). Further neurologic deterioration in ICH patients can occur due to delayed insult secondary to hematoma growth, intraventricular expansion, and perihematomal edema (2). Hematomal mass effect, evolving perihematomal edema, and perihematomal growth can result in decreased cerebral perfusion pressure (CPP), increased intracranial pressure (ICP), and herniation (2). In a systematic review and meta-analysis, about two-thirds of ICH patients who underwent ICP monitoring demonstrated at least one episode of elevated ICP (3). Despite this common occurrence, little evidence exists to support specific ICP and CPP thresholds in ICH patients and their impact on long term outcomes (4-7). A systematic review and several retrospective studies do suggest, however, that increased ICP level, duration, and variability are associated with worse outcomes and mortality (5, 7-9).

Minimally invasive surgery for ICH can reduce mass effect and may mitigate high ICP and low CPP events. However, post-operative re-hemorrhage and brain edema may oppose this potential benefit. The impact of surgical hematoma reduction on ICP and CPP levels and whether these impact patient outcomes has not been systematically studied.

We hypothesized that patients who had ICP monitors placed who underwent minimally invasive surgery (MIS) using stereotactic aspiration with alteplase would have a lower time burden and incidence of increased ICP and decreased CPP compared to patients with ICP monitors treated with medical management alone.

METHODS

Design and Study Population

We conducted a *post-hoc* exploratory analysis of data collected in the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation III (MISTIE III) trial. MSTIE III was a multicenter, randomized, open label, blinded endpoint trial that found image guided, minimally invasive surgery followed by gentle thrombolytic irrigation of the catheterized intracerebral hemorrhage clot decreased mortality, but was neutral on the primary endpoint of improved functional outcome in patients with moderate to large ICH, compared to standard medical management (9). The main inclusion criteria in the trial were (1) age 18 years or older, (2) spontaneous non-traumatic supratentorial ICH with hematoma volume >30 ml and without evidence of an underlying macrovascular cause, (3) presentation within 24 hours of symptom onset, (4) presentation Glasgow Coma Scale (GCS) \leq 14 or National Institutes of Health Stroke Scale (NIHSS) \geq 6, and (5) baseline modified Rankin score (mRS) of <2. Patients randomized to MIS (n = 250) received up to nine doses of alteplase every 8 h *via* intrahematomal catheter until hematoma volume was reduced to \leq 15 ml. The control group received standard medical care (n = 249). Details of the methodology and trial results can be found in the primary publication.

In this study, we included all 72 patients who had an ICP monitor placed. ICP monitors were inserted in a guideline supported manner per the neurosurgeons' discretion (10). The trial protocol supported ICP monitoring for "patients with a GCS of 8 or less with two observations over 8 h." The goals of ICP management were to "sustain ICP below 20 mmHg and to improve the patient's level of consciousness (9)." The protocol specified that placement of an ICP monitor had to be followed by a CT scan of the brain to monitor for ICH stability and any new areas of hemorrhage.

Standard Protocol Approvals, Registrations, and Patient Consents

The MISTIE III trial was performed at 78 hospitals in the US, Canada, Europe, Australia, and Asia following local institutional review board and country ethics approval. Written informed consent for research was obtained from all participants (or legal representatives or surrogates when applicable). The study was also approved by the Johns Hopkins Hospital institutional review board.

Measurements and Outcomes

The primary outcomes included occurrence of and percentage of ICP readings \geq 20 and 30 mm Hg, and CPP readings <60 and 70 mm Hg. ICP and CPP were recorded every 6 h for up to 6 days after placement of the ICP monitor, including prior to randomization. This time period was intended to include the full duration of the MIS treatment phase. ICP monitors included external ventricular drains (EVDs) and intraparenchymal monitors (IPMs). Choice of monitor placement ipsilateral or contralateral to the ICH was decided by each site's neurosurgical team. ICP and CPP measurements were performed according to standard of care at each center. For EVDs, drainage level and EVD management were directed TABLE 1 | Baseline demographic and radiographic characteristics by treatment group.

Gender Famale 14 (88.9%) 10 (29.4%) 0.51 Age it conserts' 56.5 (84-65) 50.5 (48-65) 0.33 Accan Amorican 8 (21.6%) 9 (27.3%) 0.83 Acan 3 (8.1%) 2 (8.6%) 0.44 Mile 26 (70.3%) 22 (86.7%) 0.44 Hypertrainion 3 (9 (7.4%) 3 (9 (7.1%) 0.37 Prior statur use 3 (7.4%) 1 (122.4%) 0.38 SEP on admission* 181.5 (162.5-21%) 164 (152-502) 0.31 DEP on admission* 181.5 (162.5-21%) 164 (152-502) 0.31 DEP on admission* 182.6 (162.8%) 2 (6.5%) 0.41 Ancho Abose 6 (15.8%) 2 (6.5%) 0.41 Ancho Abose 6 (15.8%) 2 (6.5%) 0.61 Caranter use 1 (26.0%) 3 (8.2%) 0.61 Caranter use 1 (26.3%) 0.61 0.62 Caranter use 1 (26.3%) 0.61 0.61 Caranter use 1 (26.3%) 0.61 0.62 </th <th>Demographics/Predictors</th> <th>Medical group 38/72 (52.8%)</th> <th>Surgical group 34/72 (47.2%)</th> <th colspan="2">P-value</th>	Demographics/Predictors	Medical group 38/72 (52.8%)	Surgical group 34/72 (47.2%)	P-value	
Famale14 (a (b a))10 (D (D 4.4))0.51Age at consent'360.5 (H8-63)0.03RoeAnnan American8 (D 1.6%)0 (D 7.3%)0.83Salan3 (B 1.0%)2 (D 6.1%)0.94Hypertension37 (D7.4%)33 (D 7.1%)0.94Hypertension37 (D 7.4%)0.1620.93BP on admission'115 (H2.5-274)164 (H2.2-02)0.018DBP on admission'0 (B 6.1%)2 (B 9.5%)0.64Alcoal (A Law)2 (B 9.5%)0.610.67Coorte (a (D 7.1%)2 (B 9.5%)0.610.67Alcoal (A Law)2 (B 9.5%)0.610.67Alcoal (A Law)2 (B 9.5%)0.610.61Alcoal (A Law)2 (B 1.7%)0.620.61Alcoal (A Law)2 (B 1.7%)0.630.61Alcoal (A Law)2 (B 1.7%)0.630.61Alcoal (A Law)3 (B 1.2%)0.630.61Alcoal (A Law)3 (B 1.2%)0.630.63Alcoal (A Law)3 (B 1.2%)0.63<	Gender				
App at consent" 56.5 (48-65) 50.2 (43-65) 0.23 Nace Nace Nace Atean American 8 (21.0%) 2 (0.1%) 0.28 Alian A 3 (8.1%) 2 (0.1%) 0.28 Vibrito 2 (0.1%) 2 (0.1%) 0.29 Hyportanian 3 (3 (24.%) 1 (0.2.%) 0.33 DBP or admission* 118 (16.25-21.5) 164 (152-02.0) 0.38 DBP or admission* 18 (15.6%) 2 (6.9%) 0.43 Cocaire use 1 (2.9%) 2 (6.9%) 0.43 Antoraguint use 4 (10.5%) 3 (8.2.9%) 0.41 Cocaire use 1 (2.9%) 3 (8.1.7%) 0.63 Antoraguint use 4 (10.5%) 3 (8.2.9%) 0.61 Cocaire use 1 (2.9%) 3 (8.1.7%) 0.63 Antoraguint use 8 (7-9) 8 (2.5.5%) 0.63 Coreat mode 9 (82.3.%) 0.59 0.53 Coreat mode 9 (82.3.%) 0.53 0.53 Districat and omization* 9 (2.5.	Female	14 (36.8%)	10 (29.4%)	0.51	
Race Ref CP (SP) CP (SP) Alian American B (21.6%) 0.25 Alian 3 (5.1%) 2 (6.7%) 0.94 Hypertension G 7 (57.4%) 0.87 0.94 Hypertension 13 (24.2%) 11 (2.9%) 0.87 Pror statn use 3 (7.9%) 10 (160–120) 0.16 DEP on domission* 181.5 (162.5-215) 10 (160–120) 0.71 DEP on domission* 98 (85–11%) 10 (160–120) 0.71 CAD 7 (18.4%) 2 (5.9%) 0.69 Acachal Abase 1 (20.5%) 2 (5.9%) 0.61 Anticogulant tuse 1 (20.5%) 2 (5.9%) 0.61 Anticogulant tuse 1 (20.5%) 0.81 0.31 Diabates 7 (18.4%) 8 (23.5%) 0.63 0.63 NetS at andomization* 2 (5.1%-20) 0.61 0.34 0.34 Diabates 7 (18.4%) 8 (23.5%) 0.63 0.63 PO restiti tuse 2 (7 (1.1%) 10 (1.2%) 0.63 0.63	Age at consent*	56.5 (48–65)	59.5 (48–65)	0.33	
African American B (21, 6%) 9, 02, 2(6, 1%) Asian 3 (8, 1%) 2 (6, 1%) What 20 (70, 5%) 22 (60, 7%) Hypertrasion 37 (97, 4%) 33 (97, 1%) 0.93 Phor statin use 3 (7, 9%) 1 (22, 4%) 0.35 BP on admission* 151 (5 (62, 5-215) 104 (152-521) 0.13 DBP on admission* 98 (85-119) 101 (90-120) 0.71 CAD 7 (18, 4%) 5 (14, 7%) 0.67 Cocine use 1 (22, 6%) 2 (5, 5%) 0.49 Achold Abuse 4 (10, 5%) 2 (5, 5%) 0.61 Corrent Smoker 9 (23, 7%) 5 (14, 7%) 0.33 Diabetes 7 (18, 4%) 8 (72, 5%) 0.54 Corrent Smoker 9 (23, 7%) 5 (14, 7%) 0.34 Diabetes 7 (16, 4%) 8 (72, 5%) 0.54 COS at mandomization* 2 (25, (12, 5%) 0.54 Diabetes 7 (17, 1%) 31 (61, 2%) 0.54 Diabetes 7 (71, 1%) 31 (61, 2%)	Race				
Asan 3.8.1%) 2.6.1%) White 26.07.0.3%) 22.06.7%) Whyperfanion 3.7.07.4%) 3.8.07.1%) 0.9.4 Hyperfanion 13.84.2%) 11.62.9%) 0.83 Pior statin use 3.7.07.4%) 3.8.07.1%) 0.83 SEP on admission* 9.8.65-119) 11.64.152-202) 0.7.1 DEP on admission* 9.8.65-119) 11.64.152-202) 0.7.1 CAD 7.(18.4%) 2.(5.9%) 0.67 Cacaine use 11.2.05%) 2.(5.9%) 0.61 Antiopatient use 4.(10.5.%) 3.8.2%) 0.61 Antiopatient use 11.129.0%) 8.12.55%) 0.63 Antiopatient use 7.(18.4%) 8.12.55%) 0.63 Carent Smoker 0.23.7%) 2.61.17.1%) 0.31 Diabeles 7.(18.4%) 8.12.55%) 0.63 CP thanapias used 2.6.68.4%) 2.6.72.5%) 0.63 CP to statin use 7.(18.4%) 3.8.0%) 0.53 EVD inserted 2.7.(71.1%) <td>African American</td> <td>8 (21.6%)</td> <td>9 (27.3%)</td> <td>0.83</td>	African American	8 (21.6%)	9 (27.3%)	0.83	
White 26 (PO.2%) 22 (8.7) Hypertracion 37 (97.4%) 33 (97.1%) 0.44 Hypertracion 18 (34.2%) 11 (82.4%) 0.68 Prior stafinuse 3.7 (97.4%) 14 (82-002) 0.13 SEP on admission* 181.5 (162.5-215) 14 (182-002) 0.71 CAD 7 (18.4%) 6 (14.7%) 0.67 Caciane use 1.2.6.%) 2 (5.9%) 0.48 Actorol Abuse 6 (16.3%) 2 (5.9%) 0.48 Actorol Abuse 6 (16.3%) 2 (5.9%) 0.61 Anticoagulant use 11 (29.0%) 8 (23.5%) 0.63 Carrent Bronker 9 (23.7%) 6 (14.7%) 0.63 GOS at randomization* 8 (7-9) 8 (7-10) 0.28 Diebetes 7 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 Diepoted biotation<	Asian	3 (8.1%)	2 (6.1%)		
hppersoin 37 (97.4%) 38 (97.4%) 0.94 hpperlipidemia 13 (94.2%) 11 (82.4%) 0.87 Prior statin use 37 (7.9%) 114 (82.4%) 0.13 BP on admission* 181.5 (182.5–215) 164 (182-620) 0.71 GAD 7 (18.4%) 5 (14.7%) 0.67 Cocame use 1 (2.6%) 2 (5.9%) 0.49 Achord Abase 6 (15.5%) 2 (5.9%) 0.41 Antocagulant use 4 (10.5%) 3 (8.2%) 0.81 Antopiated use 7 (18.4%) 8 (23.5%) 0.61 Current Smokar 9 (23.7%) 6 (14.7%) 0.82 Diabetes 7 (18.4%) 8 (23.5%) 0.63 EVD inserted 27 (71.1%) 3 (19.1%) 0.03 IVP Inserted 28 (6.9%) 26 (73.5%) 0.63 EVD inserted 27 (71.1%) 3 (10.0%) 0.83 Diabetes 3 (10.1%) 0.63 0.00 EVD inserted 29 (6.5%) 27 (79.4%) 0.73 EVD inserted </td <td>White</td> <td>26 (70.3%)</td> <td>22 (66.7%)</td> <td></td>	White	26 (70.3%)	22 (66.7%)		
Hyperipidemia 13 (34.2%) 11 (32.4%) 0.87 Prior statin use 3 (7.9%) 1(2.9%) 0.30 BP on admission* 1815.5 (162.5-215) 104 (152-202) 0.71 CAD 7 (18.4%) 5 (14.7%) 0.67 Cocaine use 1 (2.6%) 2 (5.9%) 0.49 Alcohol Abase 6 (15.8%) 2 (5.9%) 0.81 Anticoagulant use 1 (10.5%) 3 (8.8%) 0.81 Anticoagulant use 1 (12.90%) 8 (25.5%) 0.61 Carent Smoker 9 (23.7%) 5 (14.7%) 0.34 Diabetas 7 (18.4%) 8 (25.5%) 0.63 Cocast at randomization* 8 (7-9) 8 (7-10) 0.84 NIHSS at randomization* 8 (7-9) 8 (7-10) 0.84 VID hearted 27 (71.1%) 31 (91.2%) 0.03 CP therapies used 26 (68.4%) 2 (5.73.5%) 0.83 Diapractic parted in thrm 3 (12.6%) 3 (18.9%) 0.83 EVD inserted 2 (7.11%) 3 (16.2%) 0.83	Hypertension	37 (97.4%)	33 (97.1%)	0.94	
Prior statin use 3 (7.9%) 1 (2.9%) 0.38 SBP on admission" 1815.1 (182.5-215) 164 (182-202) 0.13 DBP on admission" 08 (85-119) 101 (90-120) 0.71 CAD 7 (18.4%) 5 (14.7%) 0.67 Cocience use 1 (2.6%) 2 (5.9%) 0.18 Anticoaguiant use 4 (10.5%) 3 (8.8%) 0.81 Antipitated use 1 (29.0%) 8 (25.5%) 0.61 Current Smoker 9 (23.7%) 8 (7.9%) 8 (7.9%) 0.84 NIHSS at randomization" 8 (7.9%) 8 (7.9%) 0.63 INPS at randomization" 2 (6 (8.4%) 2 (5 (7.5%) 0.63 INPS at randomization" 2 (7 (7.1%) 31 (01.2%) 0.03 IPM inserted 12 (6 (2.9%) 3 (8.8%) 0.03 EVD inserted 2 (7 (7.1%) 31 (01.2%) 0.03 Deap ICH location 2 (7 (7.1%) 3 (0.0%) 0.88 Deap ICH location 2 (7 (7.1%) 3 (0.0%) 0.03 Deap ICH location 3 (0.0%	Hyperlipidemia	13 (34.2%)	11 (32.4%)	0.87	
SBP on admission* 1815. (162.5-215) 164 (152-202) 0.13 DBP on admission* 08 (80-119) 101 (90-120) 0.71 CAD 7 (16.4%) 5 (14.7%) 0.67 Cocaine use 1 (2.6%) 2 (5.9%) 0.49 Altrobagulant use 6 (15.8%) 2 (5.9%) 0.81 Antipatelet use 11 (29.0%) 8 (23.5%) 0.61 Current Smoker 9 (23.7%) 5 (14.7%) 0.34 Diabetes 7 (16.4%) 8 (23.5%) 0.63 CUP therapies used 25 (73.5%) 0.63 EVD inserted 11 (29.0%) 3 (10.1%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 3 (10.0%) 0.89 Disporsito capital shift (rm) 7.9 (5.7-11.4) 3 (0.0%) 0.89 Disporsito capital shift (rm) 3.1 (14.7.2) -0.401 0.015 Disporsito capital shift (rm) 3.1 (14.7.2) -0.001 0.03 Disporsito capital shift (rm) 3.1 (14.7.2) -0.001 <td>Prior statin use</td> <td>3 (7.9%)</td> <td>1 (2.9%)</td> <td>0.36</td>	Prior statin use	3 (7.9%)	1 (2.9%)	0.36	
DBP on admission*i 98 (86–119) 101 (80–120) 0.71 CAD 7 (18.4%) 6 (14.7%) 0.67 Cocine use 1 (26%) 2 (5.9%) 0.18 Antcoagulant use 4 (10.5%) 3 (8.8%) 0.61 Antcoagulant use 4 (10.5%) 8 (25.5%) 0.61 Current Smoker 9 (23.7%) 5 (14.7%) 0.24 Diabetes 7 (18.4%) 8 (23.5%) 0.63 Current Smoker 9 (23.7%) 8 (7-10) 0.84 Diabetes 7 (18.4%) 8 (7-10) 0.84 Diabetes 7 (71.7%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (74.5%) 0.83 0.75 Diagnostic septal shift (mm) 7.9 (2.7-11.4) 3.9 (2.4,2) -0.001 Deep ICH Location 29 (67.6,5) 5 (16.5-7.2) 0.39	SBP on admission*	181.5 (162.5–215)	164 (152–202)	0.13	
CAD 7 (18.4%) 5 (14.7%) 0.67 Cocane use 1 (2.6%) 2.6.5%) 0.48 Alcobal Abuse 6 (16.8%) 2.6.5%) 0.18 Anticoagulant use 4 (10.5%) 3 (8.3%) 0.61 Anticoagulant use 1 (20.0%) 8 (3.5%) 0.61 Current Smokar 9 (23.7%) 5 (14.7%) 0.34 Diabets 7 (16.4%) 8 (23.5%) 0.65 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 23.5 (19-29) 2.5 (73.5%) 0.63 EVD Inserted 27 (71.1%) 31 (91.2%) 0.03 EVD Inserted 27 (71.1%) 31 (91.2%) 0.03 Deep ICH location 29 (76.3%) 27 (74.4%) 0.75 Diagnostic septal shift (nm) 3.1 (14-7.2) -0.8 (-2.9-1.3) <0.001	DBP on admission*	98 (85–119)	101 (90–120)	0.71	
Cacaine use 1 (2.6%) 2 (5.9%) 0.49 Alcoha Abuse 6 (15.8%) 2 (5.9%) 0.18 Antioagulant use 4 (10.5%) 3 (8.8%) 0.61 Current Smoker 9 (23.7%) 6 (14.7%) 0.34 Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 2 25 (68.4%) 2 5 (73.5%) 0.63 ICP therapies used 2 6 (88.4%) 3 (8.8%) 0.03 IPM inserted 11 (28.9%) 3 (8.8%) 0.03 IPM inserted 1 (1.1%) 3 (10.0%) 0.89 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic spetial shift (rmm) 4.7 (2-6-6.0) 5.1 (3-5-7.2) 0.39 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic priveal shift (rmm) 3.1 (1-7.2) -0.8 (-2.9-1.3) -0.001 Deta setsial shift (rmm) 3.1 (1-7.2) -0.8 (-2.9-1.3) -0.001 Deta setsia shift (rmm)	CAD	7 (18.4%)	5 (14.7%)	0.67	
Alcohol Abuse 6 (15.8%) 2 (5.9%) 0.18 Anticoagulant use 4 (10.5%) 3 (8.8%) 0.61 Current Smoker 9 (23.7%) 5 (14.7%) 0.64 Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 2.5 (51-29) 2.1 5 (7-26) 0.23 ICP therapies used 2.6 (88.4%) 25 (73.5%) 0.63 EVD inserted 2.7 (71.1%) 31 (91.2%) 0.03 IPM inserted 2.7 (71.1%) 3 (10.0%) 0.03 EVD inserted 2.7 (71.1%) 3 (10.0%) 0.88 Degordic septal shift (rm1) 7.9 (5.7-11.4) 3.9 (2.0-6.2) -0.001 Diagnostic septal shift (rm1) 7.9 (5.7-11.4) 3.9 (2.0-6.2) -0.001 Diagnostic septal shift (rm1) 7.9 (5.7-11.4) 3.9 (2.0-6.2) -0.001 Diagnostic septal shift (rm1) 7.9 (5.7-11.4) 3.9 (2.0-6.2) -0.001 Diagnostic pineal shift (rm1) 7.9 (5.7-11.4) 3.9 (2.0-6.2) -0.001	Cocaine use	1 (2.6%)	2 (5.9%)	0.49	
Anticoagulant use 4 (10.5%) 3 (8.8%) 0.81 Antiplatel use 11 (29.0%) 8 (23.5%) 0.61 Current Smoker 9 (23.7%) 5 (14.7%) 0.34 Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 22.5 (19-29) 21.5 (17-26) 0.23 ICP therapies used 26 (68.4%) 3 (8.9%) 0.03 IPM inserted 27 (71.1%) 31 (01.2%) 0.03 IPM inserted 27 (71.1%) 3 (10.9%) 0.89 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic septal shif (rmn) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.39 Diagnostic septal shif (rmn) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.001 Diagnostic inserval shif (rmn) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.001 Diagnostic inserval shif (rmn) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.001 Diagnostic inserval shif (rmn) 3.1 (1.47.2) 0.8 (-3.4) 0.01 <	Alcohol Abuse	6 (15.8%)	2 (5.9%)	0.18	
Antiplatelet use 11 (29.0%) 8 (23.5%) 0.61 Current Smoker 9 (23.7%) 5 (14.7%) 0.34 Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 23.5 (19-29) 21.5 (17-26) 0.23 ICP theraples used 26 (86.4%) 26 (73.5%) 0.63 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 Dep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic in septal shift (mm) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.001 Diagnostic in septal shift (mm) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.01 Diagnostic in septal shift (mm) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.01 Diagnostic in septal shift (mm) 3.1 (1.47.2) -0.8 (-2.9-1.3) -0.01 <	Anticoagulant use	4 (10.5%)	3 (8.8%)	0.81	
Qurrent Smoker 9 (23.7%) 5 (14.7%) 0.34 Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NHSS at randomization* 2.05 (19-29) 2.15 (17-26) 0.23 ICP therapies used 2.6 (68.4%) 2.5 (73.5%) 0.63 EVD inserted 2.7 (71.1%) 31 (91.2%) 0.03 EVD inserted 2.7 (71.1%) 3 (8.8%) 0.03 EVD inserted 2.7 (71.1%) 3 (10.0%) 0.98 Deep ICH location 2.9 (76.3%) 2.7 (79.4%) 0.75 Diagnostic septal shif (mm) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.93 EOT septal shif (mm) 3.1 (1.4-7.2) -0.8 (-2.9-1.3) <0.001	Antiplatelet use	11 (29.0%)	8 (23.5%)	0.61	
Diabetes 7 (18.4%) 8 (23.5%) 0.59 GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NIHSS at randomization* 23.5 (19-29) 21.5 (17-26) 0.23 LCP hterapies used 26 (68.4%) 25 (73.5%) 0.63 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 IPM inserted 11 (28.9%) 3 (88%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 Despicitant to ICH 31 (11.1%) 31 (00.0%) 0.88 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic septal shift (mm) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.39 EOT septal shift (mm) 3.1 (1.4-7.2) -0.8 (-2.8-1.3) -0.001 Diagnostic pineal shift (mm) 3.1 (1.4-7.2) -0.8 (-2.8-1.3) -0.001 Diagnostic pineal shift (mm) 3.1 (1.4-7.2) -0.8 (-2.4-1.3) -0.001 Diagnostic pineal shift (mm) 3.1 (0.7-4.9) 2.1 (1.2-45.0) 0.05 Stabilty (MH volume 0.3 (0-5.4) 4.3 (0.3-10.9) 0.05	Current Smoker	9 (23.7%)	5 (14.7%)	0.34	
GCS at randomization* 8 (7-9) 8 (7-10) 0.84 NIHSS at randomization* 23.5 (19-29) 21.5 (17-26) 0.23 ICP therapies used 26 (68.4%) 25 (73.5%) 0.63 IVD inserted 27 (71.1%) 31 (91.2%) 0.03 IPM inserted 11 (28.9%) 3 (6.8%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 Deep ICH location 29 (76.3%) 27 (79.4%) 0.73 Diagnostic septal shift (mm) 7.9 (5.7-11.4) 3.9 (2.0-6.2) <0.001	Diabetes	7 (18.4%)	8 (23.5%)	0.59	
NHSS at randomization* 23.5 (19-29) 21.5 (17-26) 0.23 ICP therapies used 26 (68.4%) 25 (73.5%) 0.63 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 IPM inserted 11 (28.9%) 3 (8.8%)	GCS at randomization*	8 (7–9)	8 (7–10)	0.84	
ICP therapies used 26 (68.4%) 26 (73.5%) 0.63 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 IPM inserted 11 (28.9%) 3 (8.8%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD inserted 27 (71.1%) 31 (91.2%) 0.03 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic septal shift (mm) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.39 EOT septal shift (mm) 7.9 (5.7-11.4) 3.9 (2.0-6.2) <0.001	NIHSS at randomization*	23.5 (19–29)	21.5 (17–26)	0.23	
EVD inserted 27 (71.1%) 31 (91.2%) 0.03 IPM inserted 11 (28.9%) 3 (8.8%)	ICP therapies used	26 (68.4%)	25 (73.5%)	0.63	
IPM inserted 11 (28.9%) 3 (8.8%) EVD inserted 27 (71.1%) 31 (91.2%) 0.03 EVD ipsiliateral to ICH 3 (11.1%) 3 (10.0%) 0.89 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic septal shift (nm) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.39 EOT septal shift (nm) 7.9 (5.7-11.4) 3.9 (2.0-6.2) <0.001	EVD inserted	27 (71.1%)	31 (91.2%)	0.03	
EVD inserted 27 (71.1%) 3 (91.2%) 0.03 EVD ipsilateral to ICH 3 (11.1%) 3 (10.0%) 0.89 Deep ICH location 29 (76.3%) 27 (79.4%) 0.75 Diagnostic septal shift (mm) 4.7 (2.6-6.6) 5.1 (3.5-7.2) 0.99 EOT septal shift (mm) 7.9 (5.7-11.4) 3.9 (2.0-6.2) <0.001	IPM inserted	11 (28.9%)	3 (8.8%)		
EVD ipsilateral to ICH $3 (11.7)$ $3 (10.0)$ 0.89 Deep ICH location $29 (76.3\%)$ $27 (79.4\%)$ 0.75 Diagnostic septal shift (mm) $4.7 (2.6-6.6)$ $5.1 (3.5-7.2)$ 0.39 EOT septal shift (mm) $7.9 (5.7-11.4)$ $3.9 (2.0-6.2)$ <0.001 Delta septal shift (mm) $3.1 (1.4-7.2)$ $-0.8 (-2.9-1.3)$ <0.001 Diagnostic pineal shift (mm) $3.1 (1.7-4.9)$ $2.1 (1.2-45.0)$ 0.53 EOT pineal shift $4.0 (2.5-7.1)$ $2.8 (0-4.4)$ 0.01 Delta pineal shift (mm) $1.4 (0.1-3.2)$ $0 (-1.5-1.4)$ 0.009 IVH present $21 (55.3\%)$ $22 (64.7\%)$ 0.42 Diagnostic IVH volume $0.3 (0-5.4)$ $4.3 (0.3-10.9)$ 0.56 Stability IVH volume $2.8 (0-6.9)$ $5.3 (1.9-9.4)$ 0.55 EOT IVH volume $1.1 (0.1-5.1)$ $0.8 (0.3-4.8)$ 0.83 Diagnostic IVH volume $5 (13.5\%)$ $5 (16.1\%)$ 0.76 EOT hydrocephalus $5 (13.5\%)$ $5 (16.1\%)$ 0.76 EOT hydrocephalus $8 (21.1\%)$ $3 (8.8\%)$ 0.15 Diagnostic ICH volume $44.2 (3.9-57.4)$ $45.4 (32.9-57.9)$ 0.61 Stability ICH volume $42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 EOT ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 EOT ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 Delta ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 EOT ICH volume 2	EVD inserted	27 (71.1%)	31 (91.2%)	0.03	
Deep ICH location29 (76.3%)27 (79.4%)0.75Diagnostic septal shift (mm)4.7 (2.6–6.6)5.1 (3.5–7.2)0.39EOT septal shift (mm)7.9 (5.7–11.4)3.9 (2.0–6.2)<0.001	EVD ipsilateral to ICH	3 (11.1%)	3 (10.0%)	0.89	
Diagnostic septal shift (mm) $4.7 (2.6-6.6)$ $5.1 (3.5-7.2)$ 0.39 EOT septal shift (mm) $7.9 (5.7-11.4)$ $3.9 (2.0-6.2)$ <0.001 Delta septal shift (mm) $3.1 (1.4-7.2)$ $-0.8 (-2.9-1.3)$ <0.001 Diagnostic pineal shift (mm) $3.1 (1.7-4.9)$ $2.1 (1.2-45.0)$ 0.53 EOT pineal shift (mm) $3.1 (1.7-4.9)$ $2.1 (1.2-45.0)$ 0.53 EOT pineal shift (mm) $1.4 (0.1-3.2)$ $0 (-1.5-1.4)$ 0.009 VH present $21 (55.3\%)$ $22 (64.7\%)$ 0.42 Diagnostic VH volume $0.3 (0-5.4)$ $4.3 (0.3-10.9)$ 0.05 Stability IVH volume $2.8 (0-6.9)$ $5.3 (1.9-9.4)$ 0.05 EOT IVH volume $1.1 (0.1-5.1)$ $0.8 (0.3-4.8)$ 0.83 Diagnostic ICH volume $8 (21.1\%)$ $3 (8.8\%)$ 0.15 EOT hydrocephalus $5 (13.5\%)$ $5 (16.1\%)$ 0.61 EOT hydrocephalus $8 (21.1\%)$ $3 (8.8\%)$ 0.91 EOT ICH volume $44.2 (31.9-57.4)$ $45.4 (32.9-57.9)$ 0.61 EOT Hydrocephalus $6 (21.9-57.4)$ $45.4 (32.9-57.9)$ 0.61 EOT ICH volume $47.1 (35.6-66.5)$ $15.4 (12.2-32.0)$ <0.0001 Delta ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 EOT <15 mm	Deep ICH location	29 (76.3%)	27 (79.4%)	0.75	
EOT septal shift (mm) $7.9 (5.7-11.4)$ $3.9 (2.0-6.2)$ <0.001 Delta septal shift (mm) $3.1 (1.4-7.2)$ $-0.8 (-2.9-1.3)$ <0.001 Diagnostic pineal shift (mm) $3.1 (1.7-4.9)$ $2.1 (1.2-45.0)$ 0.53 EOT pineal shift $4.0 (2.5-7.1)$ $2.8 (0-4.4)$ 0.01 Delta pineal shift (mm) $1.4 (0.1-3.2)$ $0 (-1.5-1.4)$ 0.009 IVH present $21 (55.3\%)$ $22 (64.7\%)$ 0.42 Diagnostic IVH volume $0.3 (0-5.4)$ $4.3 (0.3-10.9)$ 0.05 Stability IVH volume $2.8 (0-6.9)$ $5.3 (1.9-9.4)$ 0.05 EOT IVH volume $1.1 (0.1-5.1)$ $0.8 (0.3-4.8)$ 0.83 Diagnostic IVH volume $5 (13.5\%)$ $5 (16.1\%)$ 0.76 EOT hydrocephalus $5 (13.5\%)$ $5 (16.1\%)$ 0.76 EOT hydrocephalus $8 (21.1\%)$ $3 (8.8\%)$ 0.15 Diagnostic ICH volume $44.2 (31.9-57.4)$ $45.4 (32.9-57.9)$ 0.61 Stability ICH volume $47.1 (35.6-66.5)$ $15.4 (12.2-32.0)$ <0.0001 Delta ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 Diagnostic edema volume $26.0 (16.8-33.7)$ $21.9 (15.4-30.1)$ 0.52 Stability edema volume $40.5 (36.1-53.0)$ $31.4 (24.3-42.2)$ 0.12	Diagnostic septal shift (mm)	4.7 (2.6–6.6)	5.1 (3.5–7.2)	0.39	
Delta septal shift (mm) $3.1 (1.4-7.2)$ $-0.8 (-2.9-1.3)$ <0.001 Diagnostic pineal shift (mm) $3.1 (1.7-4.9)$ $2.1 (1.2-45.0)$ 0.53 EOT pineal shift $4.0 (2.5-7.1)$ $2.8 (0-4.4)$ 0.01 Delta pineal shift (mm) $1.4 (0.1-3.2)$ $0 (-1.5-1.4)$ 0.009 IVH present $21 (55.3\%)$ $22 (64.7\%)$ 0.42 Diagnostic IVH volume $0.3 (0-5.4)$ $4.3 (0.3-10.9)$ 0.05 Stability IVH volume $2.8 (0-6.9)$ $5.3 (1.9-9.4)$ 0.05 EOT IVH volume $1.1 (0.1-5.1)$ $0.8 (0.3-4.8)$ 0.83 Diagnostic IVH volume $5 (13.5\%)$ $5 (16.1\%)$ 0.76 EOT hydrocephalus $8 (21.1\%)$ $3 (8.8\%)$ 0.15 Diagnostic ICH volume $44.2 (31.9-57.4)$ $45.4 (32.9-57.9)$ 0.61 Stability ICH volume $47.1 (35.6-66.5)$ $15.4 (12.2-32.0)$ <0.0001 Delta ICH volume $-42.4 (-29.1-21.8)$ $-3.7 (-0.6-1.8)$ <0.0001 EOT <15 mm	EOT septal shift (mm)	7.9 (5.7–11.4)	3.9 (2.0–6.2)	< 0.001	
Diagnostic pineal shift (mm) $3.1(1.7-4.9)$ $2.1(1.2-45.0)$ 0.53 EOT pineal shift $4.0(2.5-7.1)$ $2.8(0-4.4)$ 0.01 Delta pineal shift (mm) $1.4(0.1-3.2)$ $0(-1.5-1.4)$ 0.009 IVH present $21(55.3\%)$ $22(64.7\%)$ 0.42 Diagnostic IVH volume $0.3(0-5.4)$ $4.3(0.3-10.9)$ 0.05 Stability IVH volume $2.8(0-6.9)$ $5.3(1.9-9.4)$ 0.05 EOT IVH volume $1.1(0.1-5.1)$ $0.8(0.3-4.8)$ 0.83 Diagnostic hydrocephalus $5(13.5\%)$ $5(16.1\%)$ 0.76 EOT hydrocephalus $8(21.1\%)$ $3(8.8\%)$ 0.15 Diagnostic ICH volume $44.2(31.9-57.4)$ $45.4(32.9-57.9)$ 0.61 Stability ICH volume $44.2(31.9-57.4)$ $45.4(32.9-57.9)$ 0.61 Diagnostic ICH volume $44.2(-29.1-21.8)$ $-3.7(-0.6-1.8)$ 0.0001 EOT ICH volume $-42.4(-29.1-21.8)$ $-3.7(-0.6-1.8)$ 0.0001 EOT <15 mm	Delta septal shift (mm)	3.1 (1.4–7.2)	-0.8 (-2.9-1.3)	< 0.001	
EOT pineal shift 4.0 (2.5–7.1) 2.8 (0–4.4) 0.01 Detta pineal shift (mm) 1.4 (0.1–3.2) 0 (–1.5–1.4) 0.009 VH present 21 (55.3%) 22 (64.7%) 0.42 Diagnostic IVH volume 0.3 (0–5.4) 4.3 (0.3–10.9) 0.05 Stability IVH volume 2.8 (0–6.9) 5.3 (1.9–9.4) 0.05 EOT IVH volume 1.1 (0.1–5.1) 0.8 (0.3–4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	Diagnostic pineal shift (mm)	3.1 (1.7–4.9)	2.1 (1.2–45.0)	0.53	
Deta pineal shift (mm) 1.4 (0.1–3.2) 0 (–1.5–1.4) 0.009 IVH present 21 (55.3%) 22 (64.7%) 0.42 Diagnostic IVH volume 0.3 (0–5.4) 4.3 (0.3–10.9) 0.05 Stability IVH volume 2.8 (0–6.9) 5.3 (1.9–9.4) 0.05 EOT IVH volume 1.1 (0.1–5.1) 0.8 (0.3–4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	EOT pineal shift	4.0 (2.5–7.1)	2.8 (0-4.4)	0.01	
IVH present 21 (55.3%) 22 (64.7%) 0.42 Diagnostic IVH volume 0.3 (0-5.4) 4.3 (0.3-10.9) 0.05 Stability IVH volume 2.8 (0-6.9) 5.3 (1.9-9.4) 0.05 EOT IVH volume 1.1 (0.1-5.1) 0.8 (0.3-4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9-57.4) 45.4 (32.9-57.9) 0.61 Stability ICH volume 48.5 (38.4-61.7) 48.4 (35.9-69.8) 0.91 EOT ICH volume 47.1 (35.6-66.5) 15.4 (12.2-32.0) <0.0001	Delta pineal shift (mm)	1.4 (0.1–3.2)	0 (-1.5-1.4)	0.009	
Diagnostic IVH volume 0.3 (0-5.4) 4.3 (0.3-10.9) 0.05 Stability IVH volume 2.8 (0-6.9) 5.3 (1.9-9.4) 0.05 EOT IVH volume 1.1 (0.1-5.1) 0.8 (0.3-4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9-57.4) 45.4 (32.9-57.9) 0.61 Stability ICH volume 48.5 (38.4-61.7) 48.4 (35.9-69.8) 0.91 EOT ICH volume 47.1 (35.6-66.5) 15.4 (12.2-32.0) <0.0001	IVH present	21 (55.3%)	22 (64.7%)	0.42	
Stability IVH volume 2.8 (0-6.9) 5.3 (1.9-9.4) 0.05 EOT IVH volume 1.1 (0.1-5.1) 0.8 (0.3-4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9-57.4) 45.4 (32.9-57.9) 0.61 Stability ICH volume 48.5 (38.4-61.7) 48.4 (35.9-69.8) 0.91 EOT ICH volume 47.1 (35.6-66.5) 15.4 (12.2-32.0) <0.0001	Diagnostic IVH volume	0.3 (0–5.4)	4.3 (0.3–10.9)	0.05	
EOT IVH volume 1.1 (0.1–5.1) 0.8 (0.3–4.8) 0.83 Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	Stability IVH volume	2.8 (0–6.9)	5.3 (1.9–9.4)	0.05	
Diagnostic hydrocephalus 5 (13.5%) 5 (16.1%) 0.76 EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	EOT IVH volume	1.1 (0.1–5.1)	0.8 (0.3–4.8)	0.83	
EOT hydrocephalus 8 (21.1%) 3 (8.8%) 0.15 Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	Diagnostic hydrocephalus	5 (13.5%)	5 (16.1%)	0.76	
Diagnostic ICH volume 44.2 (31.9–57.4) 45.4 (32.9–57.9) 0.61 Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	EOT hydrocephalus	8 (21.1%)	3 (8.8%)	0.15	
Stability ICH volume 48.5 (38.4–61.7) 48.4 (35.9–69.8) 0.91 EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001	Diagnostic ICH volume	44.2 (31.9–57.4)	45.4 (32.9–57.9)	0.61	
EOT ICH volume 47.1 (35.6–66.5) 15.4 (12.2–32.0) <0.0001 Delta ICH volume -42.4 (-29.1–21.8) -3.7 (-0.6–1.8) <0.0001	Stability ICH volume	48.5 (38.4–61.7)	48.4 (35.9–69.8)	0.91	
Delta ICH volume -42.4 (-29.1-21.8) -3.7 (-0.6-1.8) <0.0001 EOT <15 mm	EOT ICH volume	47.1 (35.6–66.5)	15.4 (12.2–32.0)	<0.0001	
EOT <15 mm 0 (0.00%) 16 (47.1%) 0.00 Diagnostic edema volume 26.0 (16.8–33.7) 21.9 (15.4–30.1) 0.52 Stability edema volume 40.5 (36.1–53.0) 31.4 (24.3–42.2) 0.12	Delta ICH volume	-42.4 (-29.1-21.8)	-3.7 (-0.6-1.8)	< 0.0001	
Diagnostic edema volume 26.0 (16.8–33.7) 21.9 (15.4–30.1) 0.52 Stability edema volume 40.5 (36.1–53.0) 31.4 (24.3–42.2) 0.12	EOT <15 mm	0 (0.00%)	16 (47.1%)	0.00	
Stability edema volume 40.5 (36.1–53.0) 31.4 (24.3–42.2) 0.12	Diagnostic edema volume	26.0 (16.8–33.7)	21.9 (15.4–30.1)	0.52	
	Stability edema volume	40.5 (36.1–53.0)	31.4 (24.3–42.2)	0.12	

SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; GCS, Glasgow coma scale; NIHSS, NIH stroke scale; EVD, external ventricular drain; IPM, intraparenchymal monitor; ICP, intracranial pressure; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; EOT, end of treatment. *Denotes a value provided in the format of Median (Interquartile Ranger).



by site physicians. Validation of q4h measurements with hourly measurements to not miss peak values was previously performed (5). We collected use of any ICP therapy including osmotic therapy, hyperventilation, analgesia, sedation, and where indicated to control ICP, induced coma, but not adherence data to particular thresholds.

Patient demographics and comorbidities were recorded at enrollment. CT scans were evaluated from admission, randomization (termed "stability" when all bleeding had stabilized), and end of treatment (EOT) defined as 24 h after last dose of alteplase or at similar timepoint in the medical group. These were assessed for ICH, IVH, and perihematomal edema volumes calculated using semiautomated planimetry, presence of hydrocephalus at diagnosis and EOT, pineal midline shift, and septal midline shift. CT scans were read centrally by trained image readers blinded to treatment and outcomes.

Secondary outcomes were short term and long-term mortality and poor functional outcomes at 30 and 365 days defined by modified Rankin Scale (mRS) score of 4–6. MISTIE III benefited from central blinded adjudication of outcomes using archival video recordings of individual patients.

Statistical Analysis

Demographics, baseline clinical and radiographic characteristics were compared using Wilcoxon rank sum test for non-normally distributed continuous variables, Student's t-test for normally distributed continuous variables, and Pearson Chi Square test for categorical variables. Quantitative data were expressed as median with interquartile range if non-normally distributed, mean with standard deviation for normally distributed data, and as proportions for categorical findings. We tested for intergroup differences for any ICP/CPP threshold event using the chi-squared test for categorical variables, Student's t-test for continuous variables, and the Wilcoxon Rank Sum test for ordinal variables. We also graphically compared median daily ICP and CPP levels pre and post-intervention in the MIS group and pre and post-randomization in the medical cohort. Finally, the percentage of ICP readings within each individual subject's record that were above the thresholds of 20 and 30 mmHg (% ICP readings \geq threshold) and percentage of CPP readings below the thresholds of 60 and 70 mmHg (% CPP readings < threshold) were calculated. Univariable and multivariable analyses of factors associated with % ICP readings above threshold (> 20 and \geq 30 mmHg) and with % CPP readings below threshold (<70 and <60 mmHg) were performed using binomial generalized linear models, with clustering by patient to adjust for within patient correlations.

Given that there were multiple variables and a limited data set, we used stepwise backward regression including only variables with P < 0.05 from the univariable analysis for association with either % ICP or % CPP readings above and below threshold. We also created a second model with four variables which were the most commonly selected in the step-wise regression: age, SBP on admission, IVH (presence vs. absence) and treatment group.

We fit logistic regression models for secondary outcomes to evaluate the contribution of proportion of ICP and CPP threshold events. Due to the small number of patients, models were conservatively adjusted a priori for 5 covariates included in the primary outcome analysis for the MISTIE III trial: age, diagnostic ICH volume, severity of impairment as measured by GCS and clinically established severity variables [IVH and ICH clot location (lobar vs. deep)]. Due to sample size limitations, we were not able to evaluate for effect modification of MIS on proportion of ICP/CPP threshold events. A *p*-value <0.05 was considered statistically significant. All analyses were carried out in STATA 15 (College Station, TX, USA).

RESULTS

Study Population

Of 499 randomized patients in MISTIE III, the cohort included 72 patients (14.4%) who had an ICP monitor placed; 58 patients had EVDs inserted (80.6%), while 14 patients (19.4%) had an IPM. ICP monitors were placed ipsilateral to the hematoma in 6 patients (8.3%). **Table 1** compares patients with ICP monitors by treatment group; 34/72 (47.2%) were in the MIS group and 38/72 (52.8%) were in the medical management only group. **Supplementary Table 1** compares patients with and without ICP monitors from

the MISTIE trial. Patients who had ICP monitors placed were younger, had a lower median admission GCS score and higher NIHSS score, were more likely to require mechanical ventilation, had higher ICH and IVH volume, and had hemorrhages in deep as opposed to superficial (lobar) locations.

Primary Outcomes

We recorded 1,588 ICP and CPP readings over a median (IQR) of 3 (1-6) days; temporal ICP and CPP trends are shown in Figure 1. The percentage of patients with at least 1 ICP reading above threshold was 43.1 and 16.7% for \geq 20 and \geq 30 mm Hg, respectively. Supplementary Table 2 compares patients with and without any ICP and CPP threshold event. Any ICP reading \geq 20 mm Hg was more likely in younger patients (p =0.004), without diabetes (p = 0.01), with deep ICH location (p = 0.03), higher EOT ICH volume (p = 0.04), larger EOT septal shift (p= 0.03), and in the medical management arm (p = 0.01). Any ICP readings >30 mm Hg was more frequent in patients with diabetes (p = 0.05). The percentage of patients with at least 1 CPP reading below threshold was 72.2 and 34.7% for below 70 and 60 mmHg, respectively. Any CPP reading <70 mmHg was more likely with presence of IVH (p = 0.03). Any CPP reading <60 mm Hg was more likely in patients with less antiplatelet use (p = 0.04), hydrocephalus on diagnostic CT (p = 0.01) lower GCS (p = 0.03) and larger increase in septal shift at end of treatment (p = 0.03) (Table 2).

We used general linear models to assess associations of proportion of ICP and CPP threshold events with MIS, ensuring that the models were not over fitted; first after step-wise backward regression, MIS was significantly associated with decreased proportion of ICP events \geq 20 and \geq 30 mmHg and with decreased proportion of CPP events <70 and <60 mmHg (**Table 3**). Second, we controlled for age, presence of IVH, and admission SBP and again found that MIS was associated with decreased threshold events for ICP \geq 20, and \geq 30, and CPP <70 and <60 mmHg.

Figure 2 shows median ICP and CPP by time interval. In the MIS group median ICP was significantly lower post MIS compared to pre-MIS (p = 0.001); median CPP was higher post MIS, but this difference was not significant (p = 0.07). There were no significant differences in median ICP or CPP in the medical group pre and post randomization (correlating to time of surgery).

Secondary Outcomes

In logistic regression models adjusted for the afore mentioned confounders (**Table 4**), percentage of CPP readings per patient <70 mmHg (OR = 1.71, CI = 1.12–2.59, p = 0.01), ICP readings \geq 20 mmHg (OR = 1.58, CI = 1.01–2.48, p = 0.04), and ICP readings \geq 30 mmHg (OR = 1.84, CI = 1.01–3.33, p = 0.04) were significantly associated with mortality at 1 year (**Figure 3**). Percentage of CPP readings <70 and <60 mmHg were also significantly associated with day 30 mortality. Percentage of ICP

and CPP readings above/below thresholds were not associated with functional outcomes at 1 year.

Logistic regression models for short term functional outcomes could not be defined due to all except 1 patient having a poor mRS 4-6 at day 30.

DISCUSSION

In this secondary analysis of the MISTIE III trial, we found that critical thresholds of ICP \geq 20 and 30 and CPP <60 and <70 mmHg are not infrequent in patients with ICP monitors and large ICH. This study is the first to demonstrate lower percentage of monitoring time at high ICP and low CPP values in patients undergoing clot evacuation compared to patients with ICP monitors, but without clot removal. Spending less monitoring time with high ICP and low CPP thresholds was significantly associated with lower mortality at 30 and 365 days. but not with functional outcomes at 1 year.

Prevalence of ICP and CPP Threshold Events

Elevated intracranial pressure is most likely a common occurrence following moderate to large intracranial hemorrhage where a decision is made to invasively monitor ICP. Godoy et al. reported a pooled prevalence rate of 67% of any episode of intracranial hypertension (ICP >20 mmHg) after ICH in a metanalysis of six studies (3). Factors reported to have a significant association with elevated ICP included GCS at admission, midline shift, age, hemorrhage volume and hydrocephalus. We also found a high rate of occurrence of any ICP \geq 20 mmHg which in the medical cohort was 58%, compared to 26% in the surgical cohort. In ICH patients with small parenchymal clots (< 30 ml) and large obstructive IVH, this occurrence is even higher at 73% in patients from the CLEAR III trial (11).

ICP and CPP Time Burden and Outcomes

Optimal ICP and CPP treatment thresholds and associations of threshold events with outcomes in ICH patients are less easily defined (7, 10). Recent evidence points toward time burden, rather than occurrence of any ICP or CPP event, as an important marker associated with outcomes in ICH patients (9). In patients with large IVH causing obstructive hydrocephalus requiring EVD, the percentage of monitoring time with ICP single events from >18 mmHg to >30 mmHg predicted higher short-term mortality, and successive events above 20 mmHg predicted long-term mortality as well. The MISTIE III trial excluded patients with massive IVH, but we found similar associations between long-term mortality and proportion of ICP events above common thresholds of 20 and 30 mmHg for parenchymal ICH volumes >30 ml. Although time at high ICP was not associated with short-term mortality, higher percentage of low CPP readings was significantly associated with higher odds of day 30 mortality both for <70 and <60 mmHg thresholds and at day 365 for <70 mmHg. This again is consistent with data from patients with EVD for large IVH where we previously report CPP as an independent predictor of both short- and long-term TABLE 2 | Baseline demographics and radiographic characteristics for primary outcome measures.

Demographics/Predictors	S PC ICP > 20 mm Hg	PC ICP > 20 mm Hg	PC ICP > 30 mm Hg	PC ICP > 30 mm Hg	PC CPP < 70 mm Hg	PC CPP < 70 mm Hg	PC CPP < 60	PC CPP < 60
	OR [95% CI]	P-value	OR [95% CI]	P-value	OR [95% CI]	P-value	OR [95% CI]	P-value
Male gender	1.89 (0.61–5.86)	0.27	4.30 (0.48–38.5)	0.19	0.81 (0.39–1.66)	0.56	1.11 (0.43–2.93)	0.82
Age at consent	0.93 (0.89–0.97)	0.002	0.88 (0.81–0.96)	0.002	0.99 (0.96–1.02)	0.54	0.98 (0.94–1.03)	0.41
Race								
African American								
Asian	0.32 (0.03–3.36)	0.34	8.20e-07 (2.89 2e-0.07)	0.98	0.40 (0.05–3.0)	0.38	0.32 (0.03–3.2)	0.33
White	0.36 (0.14–0.92)	0.03	0.13 (0.03–0.53)	0.005	0.73 (0.34–1.56)	0.41	0.39 (0.16–0.95)	0.04
Hypertension	0.46 (0.04–4.96)	0.52	276457.2 (2.89 2e-0.07)	0.99	0.32 (0.07–1.47)	0.14	0.18 (0.04–0.82)	0.03
Hyperlipidemia	0.37 (0.11–1.31)	0.13	0.18 (0.02-2.06)	0.17	0.85 (0.39–1.84)	0.68	0.64 (0.22-1.80)	0.40
Prior statin use	1.09 e-0.06 (2.89 2e-0.07)	0.99	3.89 e-0.6 (2.89 2e-0.07)	0.98	1.44 (0.27–7.55)	0.67	0.48 (0.01–15.93)	0.68
SBP on admission	1.01 (1.00–1.02)	0.12	1.03 (1.01–1.04)	0.004	1.00 (0.99–1.01)	0.57	1.01 (1.00–1.02)	0.04
DBP on admission	1.02 (1.00-1.04)	0.10	1.4 (1.01–1.07)	0.009	1.00 (0.98-1.02)	0.84	1.01 (0.99–1.03)	0.30
CAD	0.62 (0.14-2.75)	0.53	0.32 (0.02-5.72)	0.44	1.20 (0.49-2.96)	0.69	0.91 (0.26-3.18)	0.89
Cocaine use	1.03 (0.12-8.59)	0.98	1.11 (0.05–22.5)	0.95	0.27 (0.01-5.43)	0.39	1.22 e-6 (0)	0.98
Alcohol abuse	1.83 (0.57–5.84)	0.31	0.42 (0.02-8.59)	0.57	0.77 (0.23-2.59)	0.68	0.41 (0.05–3.01)	0.38
Anticoagulant use	0.47 (0.04–5.05)	0.53	0.51 (0.02–14.7)	0.70	1.34 (0.42-4.26)	0.62	1.17 (0.25–5.48)	0.84
Antiplatelet use	0.23 (0.04–1.18)	0.08	0.25 (0.03–2.70)	0.25	0.65 (0.27-1.56)	0.34	0.30 (0.07-1.25)	0.10
Current smoker	2.39 (0.93-6.15)	0.07	7.87 (2.09–29.8)	0.002	1.15 (0.49–2.73)	0.75	1.86 (0.71–4.86)	0.21
Diabetes	0.37 (0.97–1.95)	0.24	2.82 2e-0.07 (2.89 2e-0.07)	0.98	1.02 (0.42–2.46)	0.97	0.48 (0.11–2.03)	0.32
GCS at randomization	1.06 (0.86–1.29)	0.59	1.06 (0.79–1.42)	0.71	0.98 (084–1.16)	0.84	0.88 (0.71-1.10)	0.26
NIHSS at randomization	1.04 (0.97–1.11)	0.24	1.12 (1.02–1.23)	0.01	1.02 (0.97-1.07)	0.49	1.04 (0.97–1.11)	0.26
ICP therapies used	1.94 (0.58–6.57)	0.29	15.8 (0.23–1106.2)	0.21	0.85 (0.40–1.81)	0.68	1.46 (0.49-4.30)	0.49
Medical treatment arm	0.22 (0.07-0.69)	0.009	0.09 (0.008–0.96)	0.05	0.30 (0.14-0.65)	0.002	0.30 (0.11–0.82)	0.02
EVD inserted	0.21 (0.08-0.49)	0.00	0.08 (0.02-0.30)	0.00	0.27 (0.14-0.55)	0.00	0.33 (0.13–0.86)	0.03
EVD ipsilateral to ICH	1.02 (0.23-4.45)	0.98	1.42 (0.27-7.58)	0.68	1.28 (0.46-3.55)	0.64	0.98 (0.21-4.63)	0.98
Deep ICH location	3.42 (0.62–19.0)	0.16	9.71 (0.17–543.8)	0.27	1.01 (0.43-2.37)	0.98	1.22 (0.39–3.84)	0.73
Diagnostic septal shift (mm)	0.90 (0.76–1.06)	0.19	0.65 (0.47-0.91)	0.01	0.97 (0.86-1.09)	0.61	0.93 (0.79–1.08)	0.32
EOT septal shift (mm)	1.06 (0.96–1.16)	0.24	1.05 (0.91-1.21)	0.49	1.09 (1.02-1.16)	0.01	1.11 (1.02–1.21)	0.01
Delta septal shift	1.12 (1.01–1.24)	0.03	1.22 (1.04-1.42)	0.01	1.12 (1.04-1.21)	0.002	1.19 (1.08–1.31)	< 0.001
Diagnostic pineal shift	1.10 (0.92–1.33)	0.31	1.09 (0.83-1.43)	0.53	1.08 (0.94-1.24)	0.29	1.10 (0.92–1.31)	0.31
EOT pineal shift	1.08 (0.95–1.22)	0.25	1.01 (0.82-1.26)	0.91	1.07 (0.97-1.18)	0.18	1.09 (0.96-1.23)	0.18
Delta pineal shift	1.02 (0.88–1.20)	0.78	0.95 (0.74-1.22)	0.70	1.03 (0.92-1.16)	0.62	1.04 (0.91–1.21)	0.56
Diagnostic hydrocephalus	0.64 (0.15–2.82)	0.56	0.24 (0.01-5.86)	0.38	1.41 (0.60–3.32)	0.44	1.72 (0.62-4.81)	0.31
EOT hydrocephalus	0.58 (0.13-2.59)	0.48	0.40 (0.03-5.14)	0.48	1.18 (0.48–2.87)	0.72	1.39 (0.48-4.06)	0.54
IVH present	0.47 (0.19–1.16)	0.10	0.15 (0.03–0.73)	0.02	0.93 (0.45–1.94)	0.85	0.68 (0.28-1.66)	0.40
Diagnostic IVH volume	0.93 (0.85–1.02)	0.13	0.89 (0.7501.06)	0.18	0.96 (0.91-1.02)	0.18	0.97 (0.91–1.04)	0.38
Stability IVH volume	0.92 (0.83-1.01)	0.09	0.87 (0.72-1.04)	0.13	0.98 (0.93-1.03)	0.34	0.99 (0.93–1.04)	0.63
EOT IVH volume	0.96 (0.86–1.07)	0.43	0.83 (0.62-1.10)	0.20	1.00 (0.95–1.07)	0.75	1.02 (0.94-1.09)	0.70
Diagnostic ICH volume	0.99 (0.97–1.02)	0.49	0.96 (0.92-1.00)	0.04	1.01 (0.99–1.02)	0.84	1.00 (0.97–1.02)	0.64
Stability ICH volume	0.99 (0.96–1.01)	0.33	0.98 (0.94–1.02)	0.34	1.00 (0.99–1.02)	0.60	1.00 (0.98–1.02)	0.91
EOT ICH volume	1.01 (0.99–1.03)	0.22	1.01 (0.99–1.03)	0.42	1.01 (1.00–1.03)	0.02	1.01 (1.00–1.03)	0.16
Delta ICH volume	. ,		. ,		. ,		. ,	
EOT ICH <15 mm	0.23 (0.04–1.44)	0.12	0.17 (0.008–3.83)	0.27	0.40 (0.13–1.22)	0.11	0.54 (0.15–1.94)	0.34
Diagnostic edema volume	1.02 (1.00–1.06)	0.12	0.98 (0.94–1.04)	0.57	1.02 (0.99–1.05)	0.26	1.00 (0.97–1.04)	0.88
Stability edema volume	1.00 (0.97–1.04)	0.65	1.01 (0.98–1.04)	0.53	1.01 (0.98–1.03)	0.54	1.01 (0.99–1.03)	0.49

SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; GCS, Glasgow coma scale; NIHSS, NIH stroke scale; EVD, external ventricular drain; IPM, intraparenchymal monitor; IVH, intraventricular hemorrhage; ICH, intracerebral hemorrhage; ICP, intracranial pressure; EOT, end of treatment.

TABLE 3 | Results of multivariable model for percentage of ICP and CPP threshold readings in MIS (vs. medical management only) group patients.

Primary outcome	5							
	Percentage ICP > 20 mm Hg	Percentage ICP > 20 mm Hg	Percentage ICP > 30 mm Hg	Percentage ICP > 30 mm Hg	Percentage CPP < 70 mm Hg	Percentage CPP < 70 mm Hg	Percentage CPP < 60 mm Hg	Percentage CPP < 60 mm Hg
	OR (95% CI)	P-value	OR (95% Cl)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
MIS group								
Model 1*	0.27 (0.09–0.83)	0.02	0.04 (0.007-0.21)	< 0.001	0.32 (0.14–0.71)	0.005	0.31 (0.11–0.87)	0.03
Model 2^{\dagger}	0.27 (0.09–0.83)	0.02	0.08 (0.01–0.59)	0.01	0.31 (0.14–0.71)	0.005	0.32 (0.11–0.92)	0.03

Model 1*: Stepwise backward regression model.

Model 2^T: Multivariable model adjusted for age, presenting systolic blood pressure, IVH, and treatment group.

ICP, intracranial pressure; CPP, cerebral perfusion pressure; MIS, minimally invasive surgery; OR, odds ratio; IVH, intraventricular hemorrhage.



mortality and of short-term poor outcome at all thresholds tested from <65 to <90 mm Hg and of long-term poor outcome at <65 and <75 mm Hg. We did not find significant associations between monitored time above and below ICP/CPP thresholds, respectively, with long-term functional outcomes in this study which might be explained by insufficient power due to small sample size, and relatively infrequent ICP events >30 mmHg and CPP events <60 mmHg. Also, it is possible that parenchymal injury from large ICH volume has a greater impact on functional outcomes compared to the analysis of patients in the CLEAR III trial who had relatively small ICH. One study of 243 patients with predominantly supratentorial ICH (median volume 24 ml) showed no correlation between area under the curve of either ICP or CPP and long-term functional outcomes at 12 months, at CPP thresholds of <60 mmHg or <70 mmHg which is consistent with our findings (4).

Secondary outcomes at 30 days	Percentage ICP>20mm Hg*	Percentage ICP>20 mm Hg*	Percentage ICP>30mm Hg*	Percentage ICP>30mm Hg*	Percentage CPP<70 mm Hg	Percentage CPP<70 mm Hg	Percentage CPP<60 mm Hg	Percentage CPP<60 mm Hg
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% Cl)	P-value	OR (95% CI)	P-value
Poor neurologic outcome at 30 days	All ICP and CPP th	nresholds predict	poor neurologic function	on at 30 days per	fectly: unable to mo	del		
Mortality at day 30	1.27 (0.78–2.08)	0.34	3.24 (0.61–17.4)	0.28	1.42 (1.02–1.97)	0.04	3.00 (1.36–6.62)	0.006
Secondary outcom	nes at 365 days							
Poor neurologic outcome at 365 days	1.09 (0.69–1.71)	0.72	0.91 (0.62–1.34)	0.64	1.22 (0.86–1.73)	0.26	1.52 (0.58–3.97)	0.39
Mortality at day 365	1.58 (1.01–2.48)	0.04	1.84 (1.01–3.33)	0.04	1.71 (1.12–2.59)	0.01	2.17 (0.88–5.36)	0.09

TABLE 4 | Results of logistic regression models for short and long-term functional outcome and mortality.

*Multivariable model for neurologic function/mortality at 30 and 365 days adjusted for number of ICP/CPP readings, age, GCS, presence of IVH, ICH volume, and deep ICH location. ICP, intracranial pressure; CPP, cerebral perfusion pressure; MIS, minimally invasive surgery; OR, odds ratio; IVH, intraventricular hemorrhage; ICH, intracerebral hemorrhage; GCS, Glasgow coma scale.

Rationale for ICP Monitoring

Despite the high prevalence of increased ICP after ICH, the impact of ICP monitoring on mortality and functional outcomes is not well-established. A secondary analysis of the MISTIE III trial reported that patients with ICP monitors were more likely to have a poor functional outcome at 1 year (77.1 vs. 53.8%) without a significant influence on mortality at 1 year questioning the benefit of ICP monitoring in patients with ICH (11). Patients with ICP monitors, however, had higher clinical severity including higher ICH volume, higher IVH volume and more frequent hydrocephalus on diagnostic CT. Hydrocephalus may be an important clinical factor requiring EVD placement. EVDs in the MIS group were most commonly placed prior to surgery (67.6%) and less commonly at time of MIS. These are association studies, however, and do not imply causality or any treatment recommendations regarding ICP or CPP control. Although ICP was treated aggressively per protocol, ICP and CPP may be markers of outcome but not necessarily "modifiable" therapeutic targets.

Impact of Minimally Invasive Surgery on ICP and CPP

MISTIE III, one of the largest randomized trials of stereotactic aspiration plus thrombolysis for ICH found a mortality benefit in the surgical cohort, but did not show improvement in functional outcomes at 1 year, with the exception of patients who achieved an end of treatment ICH volume <15 ml (12, 13). The mechanism by which surgical evacuation reduces mortality, and with sufficient clot removal, potentially improves outcomes is likely multifactorial; mitigation of secondary injury pathways, edema formation and both suboptimal ICP and CPP likely play a role. After adjusting for confounding variables, patients who underwent clot volume reduction with minimally invasive surgery experienced a lower monitored time burden of ICP \geq 20 and 30 mmHg, and CPP <60 and <70 mmHg. The use of mostly EVDs in both medical and surgical patients suggests that CSF drainage likely contributed to ICP control although ICH volume



reduction also played a significant role in improving intracranial hemodynamic measures. Sun et al. investigated intraoperative changes in ICP to calculate intraoperative alterations in the "brain-hematoma" pressure gradients (14). Patients undergoing large trauma craniotomy had rapid decreases in ICP and a small "brain-hematoma" pressure gradient after the hematoma was removed. For patients undergoing keyhole endoscopy, ICP decreased slowly and the "brain-hematoma" pressure gradient was initially large, and slowly decreased. The latter procedure more closely resembles stereotactic aspiration with thrombolysis used in MISTIE III and is consistent with our finding of a slow reduction in ICP over several days as hematoma volume was gradually reduced.

LIMITATIONS

These data should be considered alongside a number of limitations. The patient sample size was relatively small, and may not be generalizable to all large ICH volume patients, given the stringent inclusion criteria of a clinical trial. We attempted to prevent over-fitting of multivariable models and may have missed important confounders. Most importantly is confounding by indication since ICP monitors were placed at the discretion of the treating physician, and most commonly in higher severity patients. However, the randomized design mitigates this concern with respect to the MIS intervention. We included patients with both intraparenchymal monitors and patients with EVDs which introduces bias into ICP readings, and the effect of CSF drainage. However, a similar number of patients in the medical and surgical treatment groups had ICP monitors placed. Despite these limitations, this dataset was systematically monitored for correctness, has well-defined objective inclusion criteria, blinded assessment of outcome and adds important information about the characteristics and sequelae of elevated ICP and low CPP in patients with ICH treated with surgical evacuation. While the population studied is small, it is important to note that a robust relationship between mitigation of ICP/CPP thresholds and mortality was identified, similar to that of another large trial for IVH (15).

CONCLUSION

This study supports the concept that ICH volume reduction with minimally invasive surgery decreases monitored time spent with high ICP and low CPP in patients with large ICH.

REFERENCES

- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol.* (2010) 9:167– 76. doi: 10.1016/S1474-4422(09)70340-0
- Wilkinson DA, Pandey AS, Thompson BG, Keep RF, Hua Y, Xi G. Injury mechanisms in acute intracerebral hemorrhage. *Neuropharmacology*. (2018) 134(Pt B):240–8. doi: 10.1016/j.neuropharm.2017.09.033
- Godoy DA, Nunez-Patino RA, Zorrilla-Vaca A, Ziai WC, Hemphill JC, 3rd. Intracranial hypertension after spontaneous intracerebral hemorrhage: a systematic review and meta-analysis of prevalence and mortality rate. *Neurocrit Care.* (2019) 31:176–87. doi: 10.1007/s12028-018-0658-x

Decreasing high ICP and low CPP burden is associated with improved short- and long-term mortality and may represent a mechanism by which mortality outcomes are improved by minimally invasive surgery.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Johns Hopkins Hospital institutional review board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MA-K and WZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. WZ and MA-K: study concept and design. MA-K, DH, and WZ: acquisition, analysis, or interpretation of data. MA-K and WZ: drafting of the manuscript. MA-K, YL, RT, RA, AH, JG, IA, DH, and WZ: critical revision of the manuscript for important intellectual content. MA-K, WZ, and RT: statistical analysis. WZ and DH: administrative, technical, or material support. WZ: study supervision. All authors contributed to the article and approved the submitted version.

FUNDING

MISTIE III was supported by a grant from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (U01NS080824) and materials grants from Genentech.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur. 2021.729831/full#supplementary-material

- Kamel H, Hemphill JC, 3rd. Characteristics and sequelae of intracranial hypertension after intracerebral hemorrhage. *Neurocrit Care*. (2012) 17:172– 6. doi: 10.1007/s12028-012-9744-7
- Ziai WC, Melnychuk E, Thompson CB, Awad I, Lane K, Hanley DF. Occurrence and impact of intracranial pressure elevation during treatment of severe intraventricular hemorrhage. *Crit Care Med.* (2012) 40:1601– 8. doi: 10.1097/CCM.0b013e318241e380
- Diedler J, Santos E, Poli S, Sykora M. Optimal cerebral perfusion pressure in patients with intracerebral hemorrhage: an observational case series. *Crit Care.* (2014) 18:R51. doi: 10.1186/cc13796
- Sykora M, Steinmacher S, Steiner T, Poli S, Diedler J. Association of intracranial pressure with outcome in comatose patients with intracerebral hemorrhage. J Neurol Sci. (2014) 342:141–5. doi: 10.1016/j.jns.2014. 05.012

- Adams RE, Diringer MN. Response to external ventricular drainage in spontaneous intracerebral hemorrhage with hydrocephalus. *Neurology*. (1998) 50:519–23. doi: 10.1212/WNL.50.2.519
- Ziai WC, Thompson CB, Mayo S, McBee N, Freeman WD, Dlugash R, et al. Intracranial hypertension and cerebral perfusion pressure insults in adult hypertensive intraventricular hemorrhage: occurrence and associations with outcome. *Crit Care Med.* (2019) 47:1125–34. doi: 10.1097/CCM.00000000003848
- Hemphill JC, 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke.* (2015) 46:2032–60. doi: 10.1161/STR.000000000000069
- Menacho ST, Grandhi R, Delic A, Anadani M, Ziai WC, Awad IA, et al. Impact of intracranial pressure monitor-guided therapy on neurologic outcome after spontaneous nontraumatic intracranial hemorrhage. *J Stroke Cerebrovasc Dis.* (2021) 30:105540. doi: 10.1016/j.jstrokecerebrovasdis.2020.105540
- Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. *Lancet.* (2019) 393:1021–32. doi: 10.1016/S0140-6736(19)30195-3
- Awad IA, Polster SP, Carrion-Penagos J, Thompson RE, Cao Y, Stadnik A, et al. surgical performance determines functional outcome benefit in the minimally invasive surgery plus recombinant tissue plasminogen activator for intracerebral hemorrhage evacuation (MISTIE) procedure. *Neurosurgery*. (2019) 84:1157–68. doi: 10.1093/neuros/nyz077
- 14. Sun G, Fu T, Liu Z, Zhang Y, Chen X, Jin S, et al. The rule of brain hematoma pressure gradient and its influence on hypertensive cerebral hemorrhage operation. *Sci Rep.* (2021) 11:4599. doi: 10.1038/s41598-021-84108-w
- 15. Hanley DF, Lane K, McBee N, Ziai w, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results

of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. *Lancet.* (2017) 389:603–11. doi: 10.1016/S0140-6736(16)32410-2

Conflict of Interest: IA and DH were awarded significant research support for Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE) III by NIH/NINDS grant U01NS080824. WZ is supported by grants R01NS102583, R01AG06993, U01NS106513 and U01NS080824. AH reports investigator-initiated funding from Regeneron, Amgen, and AMAG pharmaceuticals. IA reports grants from NIH outside the submitted work. DH reports grants from NIH including BEACH (NIA): R01AG06993, TIC (NCATS): U24TR001609, and personal fees from BrainScope, Neurotrope, Op2Lysis, and Portola Pharmaceuticals, outside the submitted work. WZ is an associate editor for Neurocritical Care and an assistant editor for Stroke and has received data monitoring committee fees from C.R. Bard, Inc. outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Al-Kawaz, Li, Thompson, Avadhani, de Havenon, Gruber, Awad, Hanley and Ziai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.